These findings indicate that TRIB2 is a new biomarker for NE-type prostate cancer and suggest that TRIB2 may contribute to enzalutamide resistance in prostate cancer cells, at least in part, by promoting lineage plasticity and phenotype switching. The gene discussed is TRIB2; the disease is prostate carcinoma.